ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2991

Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study

Pavlos Stamatis1, Carl Turesson2, Minna Willim3, Jan-Åke Nilsson4, Martin Englund5 and Aladdin Mohammad6, 1Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, 2Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 4Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, 5Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, 6Department of Medicine, University of Cambridge, Cambridge, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cancer, giant cell arteritis, outcomes and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, October 24, 2018

Title: 6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA).

Methods:

The study population consisted of 830 patients (74 % women) with biopsy-proven GCA diagnosed between 1997 and 2010. The mean age at diagnosis of GCA was 76.3 years, 77.2 years for men and 75.8 for women. The cohort was cross-linked with data from the Swedish Cancer Registry. The patients were followed from GCA diagnosis until death or December 31, 2013. All malignancies that occurred throughout the observation time were identified. Malignancies were divided into two groups; those preceding the date of the GCA diagnosis and those subsequently diagnosed. As a measure of relative risk, the age- and sex standardized incidence ratios (SIR) were calculated compared to the background population, i.e. the ratio of the incidence of observed cancer cases after the diagnosis of GCA to that of the expected number, based on cancer rates in the background population. SIRs were calculated for all types of cancer combined and for site-specific cancers.

Results:

107 patients (13%) were diagnosed with a total of 133 malignancies after the onset of GCA. Malignancies in the same organ/system were excluded, and thus 118 malignancies were included in SIR calculation. The overall risk for cancer after the GCA diagnosis was not increased with a SIR 0.98 (95% CI 0.81 – 1.17). However, there was an increased risk for myeloid leukemia SIR 2.31 (95% CI 1.06 – 4.39) and a reduced risk for breast cancer SIR 0.33 (95% CI 0.12 – 0.72) and upper gastrointestinal (GI) tract cancer SIR 0.16 (95% 0.004- 0.91). Rates of other site-specific cancers, e.g. cancer of the skin, lower GI tract, prostate or respiratory system, were not different from the expected (Table 1).

Conclusion:

The overall risk for cancer in GCA patients was not increased compared to the background population. However, we found an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancer. Possible explanations for these findings include effects of inflammation on tumor genesis and differences in other exposures that contribute to cancer risk. For example, some traditional risk factors for breast cancer, such as obesity, diabetes and late menopause, have been reported to be reduced in patients with GCA.

Table 1. Site-specific and total standardized incidence ratio of cancer in 830 patients with biopsy-proven GCA

Malignancy type

Observed, n

Expected, n

SIR

95% CI

Upper GI tract

1

6.1

0.16

0.00-0.91

Lower GI tract

18

18.1

0.99

0.59-1.57

Liver, Gallbladder, Pancreas, Peritoneum

0

4

Respiratory

8

10.4

0.76

0.33-1.51

Breast

6

18.1

0.33

0.12-0.72

Female Reproductive system

8

7.3

1.10

0.47-2.16

Prostate

15

11.5

1.30

0.73-2.15

Male Reproductive system

0

0.2

Kidneys

2

2.1

0.96

0.12-3.50

Urinary tract without kidneys

6

7.1

0.80

0.31-1.85

Skin

34

24.9

1.36

0.94-1.91

Eyes

0

0.2

CNS

1

1.3

0.76

0.02-4.30

Endocrine system

0

1.7

Sarcomas

0

0.8

Unspecified

4

5

0.80

0.22-2.07

Lymphoma

3

4.3

0.69

0.14-2.03

Multiple Myeloma

2

1.7

1.17

0.14-4.25

Leukemia

9

3.9

2.31

1.06-4.39

Myelofibrosis

1

0.5

2.12

0.05-11.85

Total

118

120.8

0.98

0.81-1.17


Disclosure: P. Stamatis, None; C. Turesson, None; M. Willim, None; J. Å. Nilsson, None; M. Englund, None; A. Mohammad, None.

To cite this abstract in AMA style:

Stamatis P, Turesson C, Willim M, Nilsson JÅ, Englund M, Mohammad A. Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/malignancies-in-giant-cell-arteritis-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/malignancies-in-giant-cell-arteritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology